Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Initiated a position; positioned for accelerated growth following the FDA approval of a breakthrough heart rhythm device and momentum in stroke reduction products.
— Kathleen A. McCarragher, Blair A. Boyer, Natasha Kuhlkin
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Boston Scientific
Boston Scientific ($BSX) represents 5.7% of the fund's portfolio. The company designs,...
A highly innovative pipeline in cardiology and other medtech spaces continues to fuel double-digit revenue growth and operating leverage. Recent stock declines...